Alessandra Ferrario is a Research Officer in health policy at LSE Health. Her research focuses on access to medicines. One of her current research projects looks at improving budget impact and cost-effectiveness of pharmaceutical products through the introduction of managed entry agreements (MEAs). She is also studying the burden and management of diabetes, both from a health and economic perspective, as part of a multi-country study in low- and middle-income countries. In previous projects she has investigated the determinants of price and utilisation differences for prescription medicines across OECD countries and issues around availability, affordability and quality of medicines in the Republic of Moldova.
Prior to joining LSE Alessandra worked on issues related to good governance for medicines for the World Health Organization. She holds an MSc in Health Policy, Planning and Financing (LSE/LSHTM), MSc in Epidemiology (Swiss Tropical and Public Health Institute, University of Basel) and BSc in Molecular Biology (University of Basel).
For a full list of Alessandra's publications, please see her LSE Research Online page
European Health Forum Gastein, Bad Hofgastein, Austria 3 October 2013, Access to medicines for non-communicable diseases in Europe.
Conference on HTA and decision-making in health care, Kazan, Russia 25 September 2013, The rationale for and use of managed entry and risk sharing agreements in pharmaceutical coverage decisions.
LSE course on pricing and reimbursement for patient representatives, London 24 June and 16 September 2013, The rationale for and use of managed entry agreements (MEAs) and their relevance for patients.
Dialogue on Diabetes, Madrid 3 June 2013, Diabetes expenditure, burden of disease and management in 5 EU countries.
Portuguese Diabetes Leadership Forum, Lisbon 23 May 2013, Research report on diabetes in 5 EU member states.
Irish Presidency Conference on Innovation and patient access to personalised medicine, Dublin 21 March 2013, Innovative payer models: Risk-sharing and managed entry agreements and their contribution to personalised medicine